BioCardia completes enrollment in low dose cohort in CardiALLO Phase I/II trial

BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction, HFrEF, and is believed to be the world’s first prospective trial of allogeneic mesenchymal stem cells, MSC, intended for treating HFrEF patients having elevated markers of heart stress and systemic inflammation.